Linked Life Data

10817729

Source:http://linkedlifedata.com/resource/pubmed/id/10817729

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
6
pubmed:dateCreated
2000-7-11
pubmed:abstractText
While in vitro results at clinically relevant concentrations do not predict abacavir (1592U89) interactions with drugs highly metabolized by cytochrome P450, the potential does exist for a pharmacokinetic interaction between abacavir and ethanol, as both are metabolized by alcohol dehydrogenase. Twenty-five subjects were enrolled in an open-label, randomized, three-way-crossover, phase I study of human immunodeficiency virus-infected male subjects. The three treatments were administration of (i) 600 mg of abacavir, (ii) 0.7 g of ethanol per kg of body weight, and (iii) 600 mg of abacavir and 0.7 g of ethanol per kg. Twenty-four subjects completed the study with no unexpected adverse events reported. Ethanol pharmacokinetic parameters were unchanged with abacavir coadministration. The geometric least squares mean area under the concentration curve extrapolated to infinite time for abacavir increased 41% (from 11.07 to 15.62 microg. h/ml), and the half-life increased 26% (from 1.42 to 1.79 h) in the presence of ethanol (mean ethanol maximum concentration in plasma of 498 microg/ml). The percentages of abacavir dose recovered in urine as abacavir and its two major metabolites were each altered in the presence of ethanol, but there was no change in the total percentage ( approximately 50%) of administered dose recovered in the 12-h collection interval. In conclusion, while a single 600-mg dose of abacavir does not alter blood ethanol concentration, ethanol does increase plasma abacavir concentrations.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/10817729-10049274, http://linkedlifedata.com/resource/pubmed/commentcorrection/10817729-10390227, http://linkedlifedata.com/resource/pubmed/commentcorrection/10817729-1471547, http://linkedlifedata.com/resource/pubmed/commentcorrection/10817729-1600045, http://linkedlifedata.com/resource/pubmed/commentcorrection/10817729-1967839, http://linkedlifedata.com/resource/pubmed/commentcorrection/10817729-2248624, http://linkedlifedata.com/resource/pubmed/commentcorrection/10817729-6618437, http://linkedlifedata.com/resource/pubmed/commentcorrection/10817729-7589030, http://linkedlifedata.com/resource/pubmed/commentcorrection/10817729-7966525, http://linkedlifedata.com/resource/pubmed/commentcorrection/10817729-8162664, http://linkedlifedata.com/resource/pubmed/commentcorrection/10817729-8627016, http://linkedlifedata.com/resource/pubmed/commentcorrection/10817729-9145874, http://linkedlifedata.com/resource/pubmed/commentcorrection/10817729-9833847
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
0066-4804
pubmed:author
pubmed:issnType
Print
pubmed:volume
44
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1686-90
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed:year
2000
pubmed:articleTitle
Pharmacokinetic interaction of abacavir (1592U89) and ethanol in human immunodeficiency virus-infected adults.
pubmed:affiliation
Glaxo Wellcome, Inc., Research Triangle Park, North Carolina 27709, USA. JAM36914@glaxowellcome.com
pubmed:publicationType
Journal Article, Clinical Trial, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Clinical Trial, Phase I